Vaccitech Archives | Be Korea-savvy

Home / Posts tagged Vaccitech

Vaccitech’s VTP-300 Induced Sustained Reductions of Surface Antigen in Patients with Chronic Hepatitis B Both as a Monotherapy and in Combination with a Single Low Dose of Anti-PD-1

OXFORD, United Kingdom, June 22 (Korea Bizwire) — Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, cancer, and autoimmune diseases, today announced an update to the interim analysis of safety and efficacy data from the HBV002 [...]

Arbutus and Vaccitech Dose First Patient in Phase 2a Clinical Trial Combining Therapies for the Treatment of Chronic Hepatitis B Virus

WARMINSTER, Pa. and OXFORD, United Kingdom, June 6 (Korea Bizwire) — Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, and Vaccitech plc (Nasdaq: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today [...]

Vaccitech Reports Promising Interim Efficacy Analysis in Phase 1b/2a Clinical Study in Chronic HBV

Interim data from 27 patients, who had completed 3 months in the HBV002 study in chronic Hepatitis B (CHB) patients, demonstrated noted changes in surface antigen (HBsAg) levels, especially in the group receiving low-dose nivolumab with the heterologous boost (VTP-300). The HBV002 study is enrolling 4 groups to explore prime-boost vector combinations, either MVA-HBV (prime) [...]

Vaccitech’s VTP-300 was Well-Tolerated and Induced T Cells Against All Targeted HBV Antigens in Both Healthy Volunteers and Patients with Chronic HBV Infection in Interim Analyses

OXFORD, United Kingdom, Nov. 12 (Korea Bizwire) — Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced results from ongoing Phase 1 and Phase 1b/2a clinical trials of VTP-300, an immunotherapy candidate in development for the treatment of CHB infection. Results to date [...]